Skip to Content
  • Pay Your Money and Hold Your Breath

    In another example of the white-knuckle here-we-go nature of the drug business, Bristol-Myers Squibb announced this morning that they’re doing a huge deal… Read More
  • The Next Immuno-oncology Frontier?

    Here’s some strong evidence for what could be the next wave of immuno-oncology: combining a TLR9 ligand with an OX40 antibody. We’re all going to ha… Read More
  • Bristol-Myers Squibb Sows Confusion

    Yesterday was a weird day for Bristol-Myers Squibb. The company announced the results of a highly anticipated clinical trial, one combining Opdivo (nivolumab) a… Read More
  • A Hard Look At Liquid Biopsies

    This new paper has generated a lot of headlines (Science news writeup here). It reports work on the long-sought “liquid biopsy” idea for cancer scre… Read More
  • The Landscape of Kinase Inhibitors

    I’ve been meaning to link to this article, which is the best overview I know of for kinase inhibitors. The authors (a large multicenter team led out of Mu… Read More
  • Watch Your Covalent Drugs Carefully

    EGFR is a growth-factor receptor protein that’s well known as a cancer target, and there are a number of drugs that target its kinase activity in order to… Read More
  • A Painful, Unacceptable Lack of Data

    Okay, this paper is not going to make a lot of people happy. The authors are reviewing oncology approvals by the European Medicines Agency (EMA) from 2009 to 20… Read More
  • Bacteria Can Make Tumors Worse

    Since the topic of bacteria effects on human disease came up here just the other day, I wanted to point out a new article that comes at this idea from a differe… Read More
Page 1 of 3812345...102030...Last »